Every 424B that Fennec Pharmaceuticals Inc. (FENC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow FENC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FENC filings page.
Fennec Pharmaceuticals Inc. is registering and issuing 670,000 common shares at $7.50 per share, for aggregate gross proceeds of $5,025,000. These shares are being sold directly to certain existing institutional shareholders in Canada (excluding Quebec) under a listed issuer financing exemption, without using a broker or placement agent. The company recently completed a separate underwritten public offering of 5,366,667 common shares at $7.50 per share, raising approximately $40,250,000 in gross proceeds.
Combined net proceeds of approximately $42,014,502 are intended first to repurchase and redeem the Petrichor convertible notes for about $21,729,455, including outstanding principal, accrued interest and a redemption fee, with the balance earmarked for working capital and general corporate purposes. After giving effect to both offerings, Fennec’s as adjusted net tangible book value as of September 30, 2025 would rise from approximately $(0.16) to $1.10 per share, resulting in immediate dilution of about $6.40 per share to new investors.
Fennec Pharmaceuticals Inc. is offering 4,666,667 common shares at $7.50 per share in an underwritten public offering, for gross proceeds of $35,000,003 and estimated net proceeds of $32,400,002 before the underwriters’ option. The company has granted underwriters a 30‑day option to buy up to 700,000 additional shares. A concurrent non‑brokered LIFE offering in Canada may raise up to an additional $5,025,000 but is not registered under this prospectus. Fennec plans to use the combined proceeds primarily to repurchase and redeem its Petrichor convertible notes for about $21,729,455 and apply any remaining funds to working capital and general corporate purposes. Following this offering and the Concurrent LIFE Offering, 33,453,496 common shares will be outstanding, or 34,153,496 if the option is fully exercised, compared with 28,116,829 shares outstanding as of November 12, 2025.
Fennec Pharmaceuticals filed a preliminary prospectus supplement for a primary offering of common shares. The company expects to use initial net proceeds to repurchase and redeem its outstanding Petrichor convertible notes, with an aggregate principal amount (inclusive of PIK interest) of approximately $19,769,076, which bear interest at prime (floor 3.5%) plus 4.5% and mature on August 19, 2027.
The offering includes a 30‑day option for underwriters to purchase additional shares. Fennec also plans a concurrent, non‑brokered Canadian LIFE offering on the same terms with certain existing institutional shareholders, which may close at the same time or shortly after and would dilute participants in this offering if completed. The common shares trade on Nasdaq as “FENC” and TSX as “FRX”; the last reported Nasdaq sale price was $7.78 on November 12, 2025. Shares outstanding were 28,116,829 as of November 12, 2025.